1. Allogeneic Hair Transplantation with Enhanced Survival by Anti-ICAM-1 Antibody with Short-Term Rapamycin Treatment in Nonhuman Primates 
Jin Yong Kim, Ji-Seon Yoon, Bo Mi Kang, Hyein Yum, Hi-Jung Park, Doo-Wan Cho, Young-Su Yang, Su-Cheol Han, Wooseok Koh, Jae- Il Lee, Kyeong Cheon Jung, Kyu Han Kim, Ohsang Kwon 
Journal of Investigative Dermatology 
Volume 137, Issue 2, Pages (February 2017)
DOI: /j.jid
Copyright © 2016 The Authors Terms and Conditions

2. Figure 1
The MD-3 antibody enhanced hair follicle allograft survival in nonhuman primates. (a) The experimental design is shown. Monkeys were divided into three groups and treated with MD-3 pretreatment plus short-term rapamycin (n = 6, MD3+IS), short-term rapamycin only (n = 5, IS), or no treatment (n = 5, Con). (b) The survival of visible hair follicle (HF) allografts in the MD3+IS, IS, and Con groups. (c) Number of visible HF allografts for each monkey. The MD3+IS group is shown as blue lines; the IS group is shown as red lines; and the Con group is shown as gray lines. (d) Representative dermoscopic images from the three groups until 4 weeks after transplantation. (e) Representative microscopic images from the three groups until 4 weeks after transplantation. H&E staining is shown (hematoxylin & eosin; scale bar = 200 μm). HTPL, hair transplantation.
Journal of Investigative Dermatology  , DOI: ( /j.jid )
Copyright © 2016 The Authors Terms and Conditions

3. Figure 2
CD3+ T-cell infiltration was delayed and reduced with MD-3 antibody treatment. Representative microscopic images of immunohistochemistry results and quantification of perifollicular (a) CD3+ T cells and (b) CD68+ macrophages in the MD3+IS, IS, and Con groups at 1, 2, and 4 weeks (2–3 HPF/HF, 1–2 HFs/monkey, immunoperoxidase; scale bar = 200 μm). (c) The T-cell-mediated cellular mechanism was the major rejection mechanism in the HF allografts (immunoperoxidase; scale bar = 200 μm). HF, hair follicle; HPF, high power field.
Journal of Investigative Dermatology  , DOI: ( /j.jid )
Copyright © 2016 The Authors Terms and Conditions